A recombinant fusion protein of colon carcinoma binding A33 single chain antibody with cytosine deaminase displayed specific antigen binding and enzyme activity in surface plasmon resonance and is catalytic activity assay. In vitro, it selectively increased the toxicity of 5-FC to A33 antigen-positive cells by 300-fold, demonstrating the potency of this ADEPT strategy.
All Science Journal Classification (ASJC) codes
- Cancer Research
- A33 antibody
- Colon carcinoma
- Directed enzyme-producing therapy (ADEPT)
- Recombinant fusion proteins
- Tumour targeting